Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00867113 · OUTCOME

Overall Survival (OS) at 60 Months

Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) · Source last updated 2018-03-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Baseline up to approximately 60 months

What was measured

Overall survival was defined as the time from the date of the first dose of study drug to the date of death. Subjects who were alive at the time of discontinuation/completion of the study were censored at the end of study date or end of treatment visit date if the subject refused to be followed post treatment. Full analysis set.

Groups in this outcome

Imatinib

All subjects received in tablet form imatinib (STI571) 400 mg once daily.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Imatinib91

Reported measurements

subjects who died
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Imatinib3Not reportedNot reportedNot reportedNot reported
subjects censored
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Imatinib88Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    subjects who died
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        88
    title
    subjects censored
denoms
  1. counts
    1. group Id
      OG000
      value
      91
    units
    Participants
description
Overall survival was defined as the time from the date of the first dose of study drug to the date of death. Subjects who were alive at the time of discontinuation/completion of the study were censored at the end of study date or end of treatment visit date if the subject refused to be followed post treatment. Full analysis set.
groups
  1. description
    All subjects received in tablet form imatinib (STI571) 400 mg once daily.
    id
    OG000
    title
    Imatinib
param Type
NUMBER
reporting Status
POSTED
time Frame
Baseline up to approximately 60 months
title
Overall Survival (OS) at 60 Months
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice